Viking Therapeutics, Inc. (VKTX)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

28.51 on 9 Oct 2026

1 buy11 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Revenue

$0.00

Net income

$359.64M

Free cash flow

$278.69M

Return on equity

-56.3%

Return on capital

-48.6%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
29 Jul 2026	Lian Brian President & CEO	Sold at will	$4.95M	5.5%
29 Jul 2026	ZANTE GREG Chief Financial Officer	Sold at will	$710.14K	9.1%
29 Jul 2026	Mancini Marianna Chief Operating Officer	Sold at will	$609.64K	4.1%
10 Mar 2026	Aubuchon Neil William Chief Commercial Officer	Bought	$149.91K	opened
5 Jan 2026	Lian Brian President & CEO	Sold at will	$7.69M	8.5%
5 Jan 2026	Mancini Marianna Chief Operating Officer	Sold at will	$1.90M	12.4%

29out of 100

Profitability 0

Financial strength 59

Growth n/a

Insiders 35

Strongest on financial strength (59), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$149.91K

1 buy, 1 buyer

Sold

$22.25M

11 sales

Planned sales

under a 10b5-1 plan